PCT International Search Report. |
Andronati, A. et al. “Synthesis of 3-aryl-1-[(4-phenyl-1-piperazinyl)butyl]indazole derivatives and their affinity to 5-HT1a serotonin and dopamine D1 receptors”, Abstract retrieved from STN Database accession no. 130:276243, 1999. |
Fujimura, Y. et al. “Indazole derivatives” Abstract retrieved from STN Database accession no 87:53281, Chugai Pharmaceutical Co., Ltd. Japan 1977. |
Fujimura, Y. et al. “Indazole derivatives” Abstract retrieved STN Database accession no 84:59450, Chugai Pharmaceutical Co., Ltd. Japan 1995. |
Nakatsuka, Masashi et al. “Preparation of pyrazole derivatives as immunosuppressants” Abstrat retrieved from STN Database accession no. 130:52417, Sumitomo Pharmaceuticals Co., Ltd., Japan 1998. |
PCT International Search Report, dated Apr. 12, 2002, for PCT Appln. No. PCT/US01/25289, Applicant Ortho McNeil Pharmaceutical, Inc. which corresponds to U.S. Appln. No. 10/075,692. |
PCT Search Report for PCT/US 01/27441 dated Jul. 18, 2002. |
Allen, E.M. et al; “Reversible Cathepsin S (CATS) Inhibitors Block Invariant Chain Degradation Both In Vitro and In Vivo” Inflammation Research (2001) Sup 2, vol. 50, p. S159 abstr. 10/04. |
Bromme, D. et al.; “Peptidyl vinyl sulphones: a new class of potent and selective cysteine protease inhibitors”, Biochem. J. (1996) 315:85-89. |
Chapman, H.A. et al.; “Emerging Roles For Cysteine Proteases in Human Biology”; Annu. Rev. Physiol. (1997) 59:63-88. |
Chapman, H.A. “Endosomal Proteolysis and MHC Class II Function”; Curr. Opin. Immunol. (1998) 10:93-102. |
Honey, K. et al.; “Role of Lysosomal Cysteine Proteinases in Antigen Presentation to CD4 T Cells”; Inflammation Research (2001) Sup. 3, vol. 50, p. S159 abstr. 10/01. |
Ll, W. et al; “Tissue Specific Expression of Cathespins and Antigen Presentation”; Inflammation Research (2001) Sup 3, vol. 50 p. S159 abstr. 10/02. |
Magill, C. et al.; “Cysteine Proteases in Antigen Presentation and Models of Inflammation”; Inflammation Research (2001) Sup 3, vol. 50, p. S159, abstr. 10/03. |
Maurer, D. et al.; “Fce Receptor 1 on Dendritic Cells Delivers IgE-Bound Multivalent Antigens into a Cathepsin S-Dependent Pathway of MHC Class II Presentation” J. Immunol. (1998) 161:2731-2739. |
McGrath, M.E. et al.; “Crystal structure of human cathepsin S”; Protein Science (1998) 7:1294-1302. |
Nakagawa, T. Y. et al.; “Impaired Invariant Chain Degradation and Antigen Presentation and Diminished Collagen-Induced Arthritis in Cathepsin S Null Mice”; Immunity (1999) 10:207-217. |
Nakagawa, T.Y. et al.: “The role of lysosomal proteinases in MHC class II-mediated antigen processing and presentation” Immunological Rev. (1999) 172:121-129. |
Nerenberg, J. B. et al.; “Design and Synthesis of N-Alkylated Saccharins as Selective a-1A Adrenergic Receptor Antagonists”; Bioorg. Med. Chem. Lett. (1998) 8:2467-2472. |
Palmer, J. T. et al.; “Vinyl Sulfones as Mechanism-Based Cysteine Protease Inhibitors”; J. Med. Chem. (1995) 38(17):3193-3196. |
Podolin, P.L. et al.; “Inhibition of Cathepsin S Blocks Invariant Chain Processing and Antigen-Induced Proliferation In Vitro and Reduces the Severity of Collagen-Induced, Arthritis In Vivo”; Inflammation Research (2001) Sup 3, vol. p. S 159 abstr. 10/05. |
Riese, R. J. et al., “Cathepsin S Activity Regulates Antigen Presentation and Immunity”; J. Clin Invest. (1998) 101 (11):2351-2363. |
Riese, R.J. et al.; “Cathepsins and COmpartmentalization in Antigen Presentation”; Cur. Opin. Immunol. (2000) 12:107-113. |
Shi, Guo-Ping, et al.; “Cathepsin S Required for Normal MHC Class II Peptide Loading and Germinal Center Development”; Immunity (1999) 10:197-206. |
Spero, D. et al.; “Design and Synthesis of Novel Cathepsin S Inhibitors”; Inflammation Research (2001) Sup. 3, vol. 50, p. S206, abstr. 079. |
Villadangos, J. A. et al.; “Degradation of Mouse Invariant Chain: Roles of Cathepsins S and D and the Influence of Major Histocompatibility Complex Polymorphism” J. Exp. Med. (1997) 186(4):549-560. |
Villadangos, J. A. et al.; “Proteases Involved in MHC Class II Antigen Presentation” Immunological Rev. (1999)172:109-120. |
Villadangos, J.A. et al.; “Proteolysis in MHC Class II Antigen Presentation: Who's in Charge?”; Immunity (2000) 12:233-239. |
Andronati, S.A. et al.: “Synthesis of 1-[4-(4-phenyl-1-piperazinyl)butyl]1,2-dihydro-3H-1,4-benzodiazepin-2-ones and 1H-indazoles and their affinity for benzodiazepine receptors”; Chemical Abstracts Number (CAN) 122:314528; (1994) 8:126-131. |
Bromme, D, et al.; “High level expression and crystallization of recombinant human cathepsin S”; Protein Science (1996) 5:789-791. |
Eberlein-Konig, et al.; “Immunohistochemical investigation of the cellular infiltrates at the sites of allergoid-induced late-phase cutaneous reactions associated with pollen allergen-specific immunotherapy”;. |
Gaga, et al; “Eosinophil Activation and T Lymphocyte Infiltration in Allergin-Induced Late Phase Skin Reactions and Classical Delayed-Type Hypersensitivity” J. Immunol. (1991) 147:816-822. |
Kirschke, H. et al.; “Cathepsin S”; Handbook of Proteolytic Enzymes; Barrett, A.J.; Rawlings, N.D.; Woessner, J.F., Editors, Academic Press (1998) 621-624. |
Riese, R.J. et al.; “Essential Role for Cathepsin S in MHC Class II-Associated Invariant Chain Processing and Peptide Loading”; Immunity (1996) 4:357-366. |
Singh, P., et al.; “Quantitative Structure Activity Relationship Studies on a New Class of Antihypertensive Agent: Derivatives of 3-Aryl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine”; Quant. Struct.-Act. Relat. (1990) 9:29-32. |
Winters, G. et al.; “Synthesis in Vitro [3H]Prazosin Displacement and in Vivo Activity of 3-Aryl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridines, a New Class of Antihypertensive”; J. Med. Chem. (1985) 28(7):934-940. |